The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone
James Berenson, MD, Berenson Cancer Center, West Hollywood, CA, shares insights into a Phase I study evaluating the addition of lenalidomide to patients with relapsed/refractory (R/R) multiple myeloma progressing on the combination of ruxolitinib and methylprednisolone. The addition of lenalidomide demonstrated clinical activity, and Dr Berenson explains that serum BCMA levels may also be used to predict which patients will respond. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Incyte Corporation
